Enterprise Value

40.69M

Cash

0.00

Avg Qtr Burn

N/A

Short % of Float

1.76%

Insider Ownership

21.32%

Institutional Own.

11.23%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
MB-107 Details
X-Linked severe combined immunodeficiency

Phase 2

Initiation

MB-207 Details
X-Linked severe combined immunodeficiency, Myelofibrosis

Phase 2

Initiation

Phase 1/2

Data readout

MB-102 (CD123) Details
High risk myelodysplastic syndromes , Blastic plasmacytoid dendritic cell neoplasm, Acute myeloid leukemia, Cancer

Phase 1/2

Data readout

MB-106 (CD20) Details
Non-Hodgkin lymphoma, Lymphoma, Chronic lymphocytic leukemia, Cancer

Phase 1/2

Data readout

MB-104 Details
Multiple myeloma, Solid tumor/s, Cancer

Phase 1

Data readout

MB-103 Details
Glioblastoma, Metastatic breast cancer to brain, Cancer

Phase 1

Data readout

MB-105 (PSCA) Details
Prostate cancer, Multiple myeloma, Cancer

Phase 1

Data readout

MB-101 (IL-13Ra2) Details
Glioblastoma, Ependymoma, Medulloblastoma, Leptomeningeal brain tumors

Phase 1

Update